Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study

不适用已完成 NCT04657523

适应症	Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
分期	不适用
申办方	Philips Clinical & Medical Affairs Global
状态	已完成
受试者人数	60 人
干预（药物）	Investigational Liver Fat Quantification Software
开始日期	2020年10月30日
完成日期	2023年1月18日
结果公布日	2026年1月23日

摘要

This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease (NAFLD). The primary objective of this clinical study is to evaluate the clinical feasibility of an investigational ultrasound technique for quantifying liver fat by comparing specific ultrasound-derived biomarkers with the liver fat percentage obtained from MRI Proton Density Fat Fraction (MRI-PDFF) measurements. All subjects enrolled in this study will undergo two investigational abdominal ultrasound examinations using the Philips EPIQ Ultrasound System and one MRI PDFF examination according to the clinical standard of care.

Correlation of the Liver Fat Percentage Reported From MRI-PDFF With Measurements Hepatorenal Index (HRI) of Ultrasound Biomarkers for Liver Fat.

Intra-procedural (1 day) · Hepatorenal Index

Investigational Ultrasound Imaging for Liver Fat Quantification	1.6 ± 0.7 Hepatorenal Index

Pearson correlation coefficient	0.5749

Correlation of the Liver Fat Percentage Reported From MRI-PDFF With Measurements of Acoustic Attenuation (dB/cm/MHZ) Ultrasound Biomarker for Liver Fat.

Intra-procedural (1 day) · dB/cm/MHZ

Investigational Ultrasound Imaging for Liver Fat Quantification	1.0 ± 0.7 dB/cm/MHZ

Pearson correlation coefficient	0.6824

Correlation of the Liver Fat Percentage Reported From MRI-PDFF With Measurements of Tissue Stiffness (kPa) Ultrasound Biomarker for Liver Fat.

Intra-procedural (1 day) · kPa

Investigational Ultrasound Imaging for Liver Fat Quantification	5.9 ± 1.8 kPa

Pearson correlation coefficient	-0.0539

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский